Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former FDAer joins GPhA regulatory affairs

Executive Summary

Former FDA Office of Generic Drugs Deputy Director Gordon Johnston is joining the Generic Pharmaceutical Association as VP-regulatory affairs. Johnston worked at FDA for 12 years, leaving OGD in January 1999 to join fellow former OGD Deputy Director Robert Pollack at Lachman Consultant Services (1"The Pink Sheet" Nov. 9, 1998, In Brief)...

You may also be interested in...



FDA Office of Generic Drugs

Deputy Director Gordon Johnston will depart from OGD Jan. 1 following acceptance of an associate position at Lachman Consultant Services. Johnston will be joining former OGD Deputy Director and Lachman VP Robert Pollock. OGD Labeling and Program Support Division Director Jerry Phillips begins a new post at the end of November as associate director for medication errors in the newly established Office of Post-marketing Drug Risk Assessment ("The Pink Sheet" Nov. 2, p. 6). Phillip's vacated position will be filled by Consumer Safety Officer Robert West. Division of Chemistry II Director Frank Holcombe will become OGD acting associate director for chemistry, and will be replaced by Florence Fong

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel